Download Bovi-Shield BRSV

Revaccination: Annual revaccination with a single dose is recommended.
Good animal husbandry and herd health management practices should be
employed.
PRECAUTIONS:
Store at 2°–7°C. Prolonged exposure to higher temperatures and/or
­direct sunlight may adversely affect potency. Do not freeze.
Use entire contents when first opened.
Sterilized syringes and needles should be used to administer this vaccine. Do not sterilize with chemicals because traces of disinfectant may
inactivate the vaccine.
Burn containers and all unused contents.
Do not vaccinate within 21 days before slaughter.
Contains gentamicin as preservative.
As with many vaccines, anaphylaxis may occur after use. Initial antidote
of epinephrine is recommended and should be followed with appropriate
supportive therapy.
This product has been shown to be efficacious in healthy animals. A
­protective immune response may not be elicited if animals are incubating
an infectious disease, are malnourished or parasitized, are stressed due
to shipment or environmental conditions, are otherwise immunocompromised, or the vaccine is not administered in accordance with label
­directions.
REFERENCES:
1. Bohlender RE, McCune MW, Frey ML, et al: Bovine respiratory syncytial
virus infection. Mod Vet Prac 63:613–618, 1982.
2. Bryson DG: Observations on outbreaks of respiratory disease in calves
associated with parainfluenza type 3 virus and respiratory syncytial virus
infection. Vet Rec 104:45–49, 1979.
3. Elazhary MASY, Roy RS, Champlin R, et al: Bovine respiratory syncytial
virus in Quebec: antibody prevalence and disease outbreak. Can J Comp
Med 44:299–303, 1980.
4. Pirie HM, Petrie L, Pringle CR, et al: Acute fatal pneumonia in calves due
to respiratory syncytial virus. Vet Rec 108:411–416, 1981.
5. Bohlender RE: Field trials of a bovine respiratory syncytial virus vaccine.
Mod Vet Prac 65:606–609, 1984.
6. Kucera CJ, Feldner TJ, Wong JS, et al: The testing of an experimental
bovine respiratory syncytial virus vaccine. Vet Med 78:1599–1604, 1983.
7. Paisley LG, Mickelsen WD, Frost OL, et al: A survey of the incidence of
prenatal mortality in cattle following pregnancy diagnosis by rectal palpation. Theriogenology 9:481–491, 1978.
8. Seidel GE, Elsden RP: Embryo transfer calves are normal. Hoards Dairy
131:914, 1986.
9. Vaillancourt D, Bierschwal CJ, Ogwa D, et al: Correlation between pregnancy diagnosis by membrane slip and embryonic mortality. JAVMA
175:466–468, 1979.
Technical inquiries should be directed to Zoetis Inc. Technical Services,
(888) 963-8471 (USA), (800) 461-0917 (Canada).
For veterinary use only
U.S. Veterinary License No. 190
Bovine Respiratory
Syncytial Virus Vaccine
Modified Live Virus
Bovi-Shield® BRSV
PRODUCT DESCRIPTION: Bovi-Shield BRSV is for vaccination of healthy
cattle, including pregnant cows, as an aid in preventing disease caused
by bovine respiratory syncytial virus (BRSV). Bovi-Shield BRSV is a freezedried preparation of an attenuated strain of BRSV propagated on an estab­­­­
lished bovine cell line, plus a sterile diluent used to rehydrate the freezedried vaccine.
DISEASE DESCRIPTION: BRSV is the etiologic agent of a specific viral
­respiratory disease of cattle of all ages, including nursing calves.1–4 Infec­
tion is characterized by rapid breathing, coughing, loss of appetite, discharge from the nose and eyes, fever, and swelling around the throat and
neck. In an acute outbreak, deaths may follow within 48 hours after onset
of signs. Pathology typically consists of subpleural and interstitial emphysema with consolidating lesions characteristic of pneumonia. Clinically,
BRSV infection may be indistinguishable from other viral infections associated with the bovine respiratory disease complex. Exacerbation of clinical
signs has been documented when concurrent BRSV and BVD or IBR
infec­tion exists.
SAFETY AND EFFICACY: Safety of Bovi-Shield BRSV was demonstrated by
controlled testing in a comprehensive cross-section of over 28,000 healthy
cattle under a variety of typical field conditions.5,6 Test animals included
calves ranging in age from 1–4 months old, bulls ranging in age from 5–9
months old, feeder cattle ranging in weight from 500–900 lb, dairy cows,
and over 1,000 pregnant cows in all trimesters of pregnancy. Bovi-Shield
BRSV was administered to test animals in two 2-mL intramuscular doses
given 4 weeks apart, and the cattle were then observed over a 14-day
­period following each dose. The overall abortion rate for vaccinated pregnant cows was no greater than the generally referenced spontaneous
abortion rate.7–9 At conclusion of the studies, participating veterinarians
reported no local or systemic adverse reactions related to use of the
­vaccine.
Efficacy of Bovi-Shield BRSV was demonstrated in challenge-of-immunity
tests conducted under federally approved protocol. All vaccinated cattle
remained clinically normal following challenge which produced typical
signs of disease in nonvaccinated control cattle.
DIRECTIONS:
General Directions: Vaccination of healthy cattle, including pregnant cows,
is recommended. Aseptically rehydrate the freeze-dried vaccine with the
sterile diluent provided, shake well, and administer 2 mL subcutaneously
or intramuscularly. In accordance with Beef Quality Assurance guidelines,
this product should be administered SC or IM in the neck region.
Primary Vaccination: Administer a single 2-mL dose to healthy cattle. To
avoid possible maternal antibody interference with active immunization,
calves vaccinated before the age of 6 months should be revaccinated
­after 6 months of age.
Zoetis Inc.
Kalamazoo, MI 49007, USA
30063200
30063200
Time/Date:
30063200.indd 1
2/11/14 10:58 AM
Project No.
Artwork Number
12274
Description
Dimensions
Drawing No. 2.9375” x 5.75” Folds to: 1” x 5.75”
Additional Info:
GA
L. Nelson
Rev
1
GA
US
SKU No.
Item
4252000
Insert
Colors:
EDITOR’S COPY
Black
Mgr J. Rustad
GS C. Teachout
Country
30063200Bovi-Shield
GS:DATE:
Dieline
PR
GS / ART REV (LCA)
GS / ART REV (FA)
CHANGES
CHANGES
CHANGES
OK
OK
OK